Literature DB >> 6491654

Behavioral and biochemical effects of subchronic treatment with (-)3-(3-hydroxyphenyl)-N-n-propylpiperidine in the rat: dopamine receptor sensitivity and tolerance.

S Ahlenius, V Hillegaart, O Magnusson, J Lundström.   

Abstract

Male Sprague-Dawley rats were treated for 3 weeks with (-)3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP). Twenty-four hours, but not 72 hours, after withdrawal of the treatment there was an increase in locomotor activity in comparison with saline treated controls. At the same time there was a decrease in striatal DOPAC and HVA and an increased locomotor activity response to apomorphine, indicating supersensitive dopamine receptors. There was no evidence for behavioral tolerance since the suppression of locomotor activity after an acute dose of (-)3-PPP was the same in (-)3-PPP-pretreated as in saline-treated controls. Plasma levels of (-)3-PPP in these animals were, however, slightly decreased.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491654     DOI: 10.1007/bf01245028

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  12 in total

1.  Drug-induced dopaminergic supersensitivity.

Authors:  K E Moore; J E Thornburg
Journal:  Adv Neurol       Date:  1975

2.  Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment.

Authors:  P F Vonvoigtlander; E G Losey; H J Triezenberg
Journal:  J Pharmacol Exp Ther       Date:  1975-04       Impact factor: 4.030

3.  Alteration in the action of cholinergic and anti cholinergic drugs after chronic haloperidol: indirect evidence for cholinergic hyposensitivity.

Authors:  G Gianutsos; H Lal
Journal:  Life Sci       Date:  1976-03-01       Impact factor: 5.037

4.  Adaptational phenomena in neuroleptic treatment.

Authors:  I M Nielsen; A V Christensen; J Hyttel
Journal:  Adv Biochem Psychopharmacol       Date:  1978

Review 5.  Supersensitivity of pituitary dopamine receptors involved in the inhibition of prolactin secretion.

Authors:  L Annunziato; A Quattrone; G Schettini; G Di Renzo
Journal:  Adv Biochem Psychopharmacol       Date:  1980

6.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]-N-n-propylpiperidine).

Authors:  D Jackson; A Carlsson; S Hjorth; P Lindberg
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

8.  Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.

Authors:  J Arnt; K P Bøgesø; A V Christensen; J Hyttel; J J Larsen; O Svendsen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.

Authors:  J L Waddington; A J Cross; S J Gamble; R C Bourne
Journal:  Science       Date:  1983-04-29       Impact factor: 47.728

10.  Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography--electrochemical detection system.

Authors:  O Magnusson; L B Nilsson; D Westerlund
Journal:  J Chromatogr       Date:  1980-12-12
View more
  2 in total

Review 1.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

2.  Sub-chronic administration of (-)-3-PPP and central dopamine receptor sensitivity changes.

Authors:  S Hjorth; D Clark; K Svensson; A Carlsson; O Thorberg
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.